BACKGROUND: Radiotherapy (rt) has been the standard treatment for early oropharyngeal cancer, achieving excellent outcomes, but with significant toxicities. Transoral robotic surgery (tors) has emerged as a promising alternative. A decision aid (da) can help to establish patient treatment preferences. METHODS: A da was developed and piloted in 40 healthy adult volunteers. Assuming equal oncologic outcomes of the treatments, participants indicated their preference. The treatment trade-off point was then established, and participant perceptions were elicited. RESULTS: More than 80% of participants initially selected tors for treatment, regardless of facilitator background. For all participants, the treatment trade-off point changed after an average 15% cure benefit. Treatment toxicities, duration, novelty, and perceptions all influenced treatment selection. All subjects valued the da. CONCLUSIONS: A da developed for early oropharyngeal cancer treatment holds promise in the era of shared decision-making. Assuming equal cure rates, tors was preferred over rt by healthy volunteers.
BACKGROUND: Radiotherapy (rt) has been the standard treatment for early oropharyngeal cancer, achieving excellent outcomes, but with significant toxicities. Transoral robotic surgery (tors) has emerged as a promising alternative. A decision aid (da) can help to establish patient treatment preferences. METHODS: A da was developed and piloted in 40 healthy adult volunteers. Assuming equal oncologic outcomes of the treatments, participants indicated their preference. The treatment trade-off point was then established, and participant perceptions were elicited. RESULTS: More than 80% of participants initially selected tors for treatment, regardless of facilitator background. For all participants, the treatment trade-off point changed after an average 15% cure benefit. Treatment toxicities, duration, novelty, and perceptions all influenced treatment selection. All subjects valued the da. CONCLUSIONS: A da developed for early oropharyngeal cancer treatment holds promise in the era of shared decision-making. Assuming equal cure rates, tors was preferred over rt by healthy volunteers.
Authors: Fernando Danelon Leonhardt; Harry Quon; Marcio Abrahão; Bert W O'Malley; Gregory S Weinstein Journal: Head Neck Date: 2011-04-05 Impact factor: 3.147
Authors: William M Mendenhall; Robert J Amdur; Christopher G Morris; Jessica M Kirwan; Jonathan G Li Journal: Laryngoscope Date: 2010-11 Impact factor: 3.325
Authors: Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman Journal: Cancer Date: 2016-03-11 Impact factor: 6.860
Authors: Grace A Lin; David S Aaronson; Sara J Knight; Peter R Carroll; R Adams Dudley Journal: CA Cancer J Clin Date: 2009-10-19 Impact factor: 508.702
Authors: Anthony C Nichols; John Yoo; J Alex Hammond; Kevin Fung; Eric Winquist; Nancy Read; Varagur Venkatesan; S Danielle MacNeil; D Scott Ernst; Sara Kuruvilla; Jeff Chen; Martin Corsten; Michael Odell; Libni Eapen; Julie Theurer; Philip C Doyle; Bret Wehrli; Keith Kwan; David A Palma Journal: BMC Cancer Date: 2013-03-20 Impact factor: 4.430